Forterra Announces First Quarter 2019 Earnings Schedule
IRVING, Texas, April 30, 2019 (GLOBE NEWSWIRE) -- Forterra, Inc. (“Forterra”) (NASDAQ: FRTA), plans to release first quarter 2019 financial results after the market close on Monday, May 6, 2019. A conference call to review financial results will be held on Tuesday, May 7, 2019 at 10:00 a.m. Eastern Time (9:00 a.m. Central). Hosting the call will be Jeff Bradley, Chief Executive Officer, and Charlie Brown, Executive Vice President and Chief Financial Officer.
CONFERENCE CALL AND WEBCAST DETAILS
Event: Q1 2019 Forterra Inc. Earnings Call
Date: Tuesday, May 7, 2019
Time: 10:00 a.m. Eastern Time (9:00 a.m. Central)
Conference Call Information
Participant Passcode: 7375814
A replay of the conference call and archive of the webcast will be available within 24 hours after the call on the “Events & Presentations” page under the investor section of the Company's website at http://forterrabp.com
Forterra is a leading manufacturer of water and drainage pipe and products in the U.S. and Eastern Canada for a variety of water-related infrastructure applications, including water transmission, distribution, drainage and stormwater systems. Based in Irving, Texas, Forterra’s product breadth and scale help enable it to provide critical infrastructure components for a broad spectrum of construction projects. The quality of our products and the expertise of our people are the backbone of our success. For more information on Forterra, visit http://forterrabp.com.
Executive Vice President and Chief Financial Officer
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Hofseth Biocare ASA: ENTERS INTO A CONSULTANCY AGREEMENT WITH JAMES BERGER – CONTEMPLATED US LISTING18.10.2019 08:05:00 CEST | Press release
Hofseth BioCare ASA ("HBC") has today entered into a consultancy agreement with James Berger (through his company Nevera AG). Mr. Berger is a dual British and Italian citizen currently residing in Switzerland who has previously worked as an investment banker with Goldman Sachs International (London), JP Morgan (London), MAN Investments PLC and Millennium Capital Management LLC. He has a broad network with the largest investment banks and institutional investors in Europe and globally. Mr. Berger has already successfully assisted HBC with its oversubscribed private placement of NOK 118 million that was directed towards international private investors and institutional funds. He has recently also facilitated the sale of additional shares in HBC from certain existing shareholders to new international investors. Under the consultancy agreement, Mr. Berger will assist HBC with certain intermediary services, in establishing a wider base of international investors. Mr. Berger and HBC believe
Yara announces share buy-backs18.10.2019 08:02:00 CEST | Press release
Oslo, 18 October 2019: Yara International ASA plans to buy back 0.5% of its outstanding shares by the end of 2019. Including the proportional redemption of shares owned by the Norwegian state, the total buyback and redemption will amount to approximately 0.8% of shares outstanding, equivalent to approximately NOK 800 million at today’s share price. Yara's targeted capital structure is a mid- to long-term Net debt/EBITDA range of 1.5-2.0 and a net debt/equity ratio below 0.60. Subject to these requirements, Yara's ordinary dividend shall be 50% of net income. Shareholder returns are distributed primarily as cash, with share buy-backs as a supplemental lever. Yara’s net debt/EBITDA as of 30 September 2019 would be close to 2.0 including the full effect of the announced buyback. The buy-backs are part of a program authorized by the Annual General meeting held 7 May 2019, which authorized Yara to buy back up to 5% (13,620,131 shares) of its share capital before its 2020 Annual General Meet
Yara reports higher results, delivering operational and commercial improvement18.10.2019 08:00:00 CEST | Press release
Oslo, 18 October 2019: Third-quarter net income after non-controlling interests was USD 74 million (USD 0.27 per share), compared with USD 98 million (USD 0.36 per share) a year earlier. Excluding currency effects and special items, the result was USD 0.94 per share compared with USD 0.50 per share in third quarter 2018 . Third-quarter EBITDA excluding special items was USD 630 million, up from USD 402 million a year earlier, mainly reflecting higher nitrogen upgrading margins and strong premium product deliveries. “Yara delivers significantly improved results in third quarter, with EBITDA excluding special items and IFRS 16 up 49%. The results reflect lower energy cost, higher production and strong premium product deliveries,” said Svein Tore Holsether, President and Chief Executive Officer of Yara. "I am pleased to see our results improve within all business segments, with the strongest increase in New Business. Our return on capital continues its positive trend, and our main priorit
Yara med høyere resultat, operasjonell og kommersiell forbedring18.10.2019 08:00:00 CEST | Pressemelding
Oslo, 18. oktober 2019: Nettoresultat etter minoritetsinteresser for tredje kvartal var på USD 74 millioner (USD 0,27 per aksje), mot USD 98 millioner (USD 0,36 per aksje) for samme periode i fjor. Korrigert for valutaeffekter og spesielle poster var resultatet på USD 0,94 per aksje, mot USD 0,50 per aksje i tredje kvartal 2018. EBITDA eksklusive spesielle poster for tredje kvartal var på USD 630 millioner, opp fra USD 402 millioner ett år tidligere, og reflekterer høyere nitrogen oppgraderingsmarginer og sterke premium-leveranser. «Yara leverer betydelig bedre resultater i andre kvartal, med EBITDA eksklusive spesielle poster og IFRS 16 opp 49 %. Resultatet reflekterer lavere energikostnader, høyere produksjon og sterke premium-leveranser» sier Svein Tore Holsether, konsernsjef i Yara. «Jeg er fornøyd med at vi leverer resultatforbedring innen alle forretningsområder, med sterkest økning i New Business. Yaras avkastning fortsetter å øke, og hovedprioriteten fremover vil fortsatt være
SBM Offshore successful bidder for partner’s minority ownership in SBM Offshore operated FPSO companies18.10.2019 07:30:00 CEST | Press release
October 18, 2019 Further to the announcement dated September 30, 2019 confirming its participation in the public sale auction of the equity ownership of Serviços de Petróleo Constellation S.A. (“Constellation”) in the lease and operating companies related to five Brazilian FPSOs (“the entities”), SBM Offshore confirms it has been formally designated as the successful bidder. Completion of the transaction remains subject to various conditions precedent, including consent from client Petrobras and approval by the local antitrust authority CADE (“Conselho Administrativo de Defesa Econômica”). The total consideration for the equity ownership, excluding associated non-recourse project debt, is c. US$150 million. The transaction includes the minority stake held by affiliated companies of Constellation in the entities related to the following five FPSOs (with Constellation’s ownership percentage in brackets): Cidade de Paraty (20%), Cidade de Ilhabela (12.75%), Cidade de Marica (5%), Cidade d
Roche announces FDA approval of Xofluza (baloxavir marboxil) for people at high risk of developing influenza-related complications18.10.2019 07:00:00 CEST | Press release
Single-dose Xofluza is the first and only antiviral medicine indicated specifically for patients at high risk of developing serious complications from influenza (flu) The Centers for Disease Control and Prevention (CDC) defines people at high risk of serious flu complications as those who have conditions such as asthma, chronic lung disease, diabetes, heart disease or morbid obesity, or adults 65 years of age or older1 Basel, 18 October 2019 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Xofluza™ (baloxavir marboxil) for the treatment of acute, uncomplicated influenza, or flu, in people 12 years of age and older who have been symptomatic for no more than 48 hours and who are at high risk of developing flu-related complications. Xofluza is a first-in-class, one-dose oral medicine with a novel proposed mechanism of action that inhibits polymerase acidic endonuclease, an enzyme